Diferencia entre revisiones de «Allopurinol»
Sin resumen de edición |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| (No se muestra una edición intermedia del mismo usuario) | |||
| Línea 51: | Línea 51: | ||
==Comments== | ==Comments== | ||
==Indications by Condition== | |||
''The following table is automatically generated from disease/condition pages across WikEM.'' | |||
{{#ask:[[Has DrugName::Allopurinol]] | |||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=table | |||
|headers=plain | |||
|mainlabel=- | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | |||
==See Also== | ==See Also== | ||
Revisión actual - 21:58 20 mar 2026
Administration
- Type: xanthine oxidase inhibitor
- Dosage Forms: tablet, powder for injection
- Routes of Administration: IV, PO
- Common Trade Names: Zyloprim, Aloprim
Adult Dosing
- Gout, nephrolithiasis: 100-300mg PO 1-2 times daily
- Tumor lysis syndrome/hyperuricemia in liquid malignancies: 200-800 mg PO or IV daily
Pediatric Dosing
- <6yo: 150 mg PO daily for 2 to 3 days, then adjust dose for maintenance
- >6yo: 300 mg PO daily for 2 to 3 days, then adjust dose for maintenance
- 200 mg/m(2)/day IV
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk minimal
Renal Dosing
- CrCl 10-20: 200 mg PO or IV daily
- CrCl 3-10: max daily dose 100 mg PO or IV
- CrCl <3: 100mg PO or IV at "extended intervals"
Hepatic Dosing
- No adjustment
Contraindications
- Allergy to class/drug
- Concomitant use with didanosine
Adverse Reactions
Serious
- Cardiac arrest, ventricular fibrillation, heart failure
- SJS/TEN
- Agranulocytosis, myelosuppression, aplastic anemia, thrombocytopenia, eosinophilia
- DIC
- Renal failure
- Respiratory distress
- Hepatotoxicity, granulomatous hepatitis
- Stroke, seizure
Common
- Nausea, vomiting
- Rash, pruritus
Pharmacology
- Half-life: 1-2 hours
- Metabolism: Hepatic
- Excretion: Renal
Mechanism of Action
- Inhibits xanthine oxidase (converts hypoxanthine/xanthine to uric acid), leading to decreased uric acid concentration
Comments
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Tumor lysis syndrome | 200-400 mg/m2 q12hr (or 10 mg/kg/day PO divided q8hr) | Xanthine oxidase inhibitor (prevention only) | IV/PO | Adult |